A Phase Ib trial was launched by Pfizer for its mini-dystrophin drug candidate PF-06939926 to treat patients with Duchenne muscular dystrophy. The company expects to enroll 12 patients in the trial for the drug, which it received as part of its acquisition of Bamboo Therapeutics, and aims to have preliminary results of the study in the first half of 2019.
Pfizer enrolls first patient in Duchenne muscular dystrophy study
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.